

QUALITY ASSURANCE DEPARTMENT

ANALYTICAL METHOD VALIDATION/VERIFICATION PROTOCOL FOR CIPROFLOXACIN TABLETS USP 500 MG

# ANALYTICAL METHOD VALIDATION REPORTS FOR CIPROFLOXACIN TABLETS BP 500 mg



QUALITY ASSURANCE DEPARTMENT

# ANALYTICAL METHOD VALIDATION/VERIFICATION PROTOCOL FOR CIPROFLOXACIN TABLETS USP 500 MG

**Product Name** Ciprofloxacin Tablets 500 mg

**Ingredient** Ciprofloxacin Hydrochloride

**Label Claim** Each film coated tablet contains

Ciprofloxacin Hydrochloride BP

Eq. to Ciprofloxacin -----500 mg

**Test Method** By Liquid Chromatography

### **Specificity (Diluents Interference):**

### **Placebo Preparation:**

A placebo solution was prepared same as the formulation except for the addition of the active ingredients.

Here used the placebo solution area at 278 nm, Observation Result: Nil

### **Conclusion for Specificity:**

We observed that at wavelength 278 nm there is no significant area for placebo (Diluents) for Ciprofloxacin assay method. Therefore specificity of the method considered acceptable.

### **System Accuracy:**

The system precision of the above method was carried out by taking area for six times of the sample preparation of exact weight.

Text data collection sheet:

| Serial No. | Area |
|------------|------|
| 1.         |      |
| 2.         |      |
| 3.         |      |
| 4.         |      |
| 5.         |      |
| 6.         |      |
| Mean       |      |
| % RSD      |      |

Acceptance Criteria: RSD is not more than 2.0%.

### **Linearity/ Accuracy:**

**Definition:** 

The Linearity of an analytical method is its ability to elicit test results that are directly, or by a well



QUALITY ASSURANCE DEPARTMENT

# ANALYTICAL METHOD VALIDATION/VERIFICATION PROTOCOL FOR CIPROFLOXACIN TABLETS USP 500 MG

Defined mathematical transformation, proportional to the concentration of the analyte in samples Within a given range. Linearity is usually expressed in terms of the variance around the slope of the Regression line calculated according to an established mathematical relationship from test results Obtained by the analysis of sample with varying concentration of analyte.

### Range:

#### **Definition**:

The Range of an analytical method is the interval between the upper & lower level of analyte that have been demonstrated with precision, accuracy & linearity using the method as written. The Range is normally expressed in same units as test results e.g. Percent or Parts per million, obtained by the analytical method.

**Assay:** (Limit: 90.0 % to 110.0 % of the labeled amount).

### **Chromatographic Condition:-**

- a stainless steel column 25 cm X 4.6 mm, packed with octadecylesilane bonded to porous silica (5um),
- Flow rate 1.5ml per minute,
- spectrophotometer set at 278 nm,
- Injection volume 10 μl.
- Column temperature of 40°.

**Mobile Phase:** A mixture of 13 volumes of Acetonitrile and 87 volumes of a 0.245% w/v solution of Orthophosphoric acid the pH of which has been adjusted to 3.0 with triethylamine. Then degas and filter through with  $0.45~\mu m$  filter paper.

#### **Standard preparation:**

Weigh accurately-----mg (about 116 mg) of Ciprofloxacin Hydrochloride working standard in 100ml volumetric flask add 50 ml of mobile phase and sonicate to completely dissolve, shake and makeup 100 ml with mobile phase & filter. Take 5.0ml and dilute to 25 ml with mobile phase & shake.

#### **Sample Preparation:**

Weigh accurately as required quantities of the sample powdered tablets in 100ml volumetric flask add 50 ml of mobile phase and sonicate to completely dissolve, shake and makeup 100 ml with mobile phase & filter. Take 5.0 ml and dilute to 25 ml with mobile phase & shake.

### **Chromatographic system:**



QUALITY ASSURANCE DEPARTMENT

# ANALYTICAL METHOD VALIDATION/VERIFICATION PROTOCOL FOR CIPROFLOXACIN TABLETS USP 500 MG

Inject the standard and sample solutions. If the tailing factor more than 2.0 and column efficiency is less than 2000 theoretical plates the test is not valid. The relative standard deviation for replicate injection is not more than 2.0 %. Inject the test solution and reference solution.

### Test data collection sheet:

| S.No. | Standards  | Area |
|-------|------------|------|
| 1.    | Standard-1 |      |
| 2.    | Standard-2 |      |
| 3.    | Standard-3 |      |
| 4.    | Standard-4 |      |
| 5.    | Standard-5 |      |
| 6.    | Standard-6 |      |
| 7.    | Mean       |      |
| 8.    | %RSD       |      |

Acceptance Criteria: RSD is not more than 2.0%

| Sample      | s    | Sample Area | Mean |
|-------------|------|-------------|------|
| Sample-A-01 | 80%  |             |      |
| Sample-A-02 | 80%  |             |      |
| Sample-A-03 | 80%  |             |      |
| Sample-B-01 | 90%  |             |      |
| Sample-B-02 | 90%  |             |      |
| Sample-B-03 | 90%  |             |      |
| Sample-C-01 | 100% |             |      |
| Sample-C-02 | 100% |             |      |
| Sample-C-03 | 100% |             |      |
| Sample-D-01 | 110% |             |      |
| Sample-D-02 | 110% |             |      |
| Sample-D-03 | 110% |             |      |
| Sample-E-01 | 120% |             |      |
| Sample-E-01 | 120% |             |      |
| Sample-E-01 | 120% |             |      |

### **Calculation:**



QUALITY ASSURANCE DEPARTMENT

# ANALYTICAL METHOD VALIDATION/VERIFICATION PROTOCOL FOR CIPROFLOXACIN TABLETS USP 500 MG

#### **Data Collection:-**

| Concentration | Concentration | Corr.       | Sample mean | % Recover | Corr. Coefficient |
|---------------|---------------|-------------|-------------|-----------|-------------------|
| (µg/ml)       | in %          | Coefficient | area        |           |                   |
|               | 80.0          |             |             |           |                   |
|               | 90.0          |             |             |           |                   |
|               | 100.0         | 1.0         |             |           |                   |
|               | 110.0         |             |             |           |                   |
|               | 120.0         |             |             |           |                   |

#### **Precision:**

The precision of an analytical method is the degree of agreement among individual test results when the method is applied repeatedly to multiple sampling of a homogeneous sample. The precision of the analytical method is usually expressed as Standard deviation or relative standard deviation (coefficient of variation) of a series measurement. The precision may be measured of either the degree of reproducibility or of repeatability of the analytical method on the normal operating condition.

### **Precision – Method precision:**

### **Chromatographic Condition:-**

- a stainless steel column 25 cm X 4.6 mm, packed with octadecylesilane bonded to porous silica (5um),
- Flow rate 1.5ml per minute,
- spectrophotometer set at 278 nm,
- Injection volume 10 μl.
- Column temperature of 40°.

### **Mobile Phase:**

A mixture of 13 volumes of Acetonitrile and 87 volumes of a 0.245% w/v solution of Orthophosphoric



QUALITY ASSURANCE DEPARTMENT

# ANALYTICAL METHOD VALIDATION/VERIFICATION PROTOCOL FOR CIPROFLOXACIN TABLETS USP 500 MG

acid the pH of which has been adjusted to 3.0 with triethylamine. Then degas and filter through with 0.45  $\mu m$  filter paper.

### **Standard preparation:**

Weigh accurately-----mg (about 116mg) of Ciprofloxacin Hydrochloride working standard in 100ml volumetric flask add 50 ml of mobile phase and sonicate to completely dissolve, shake and makeup 100 ml with mobile phase & filter. Take 5.0ml and dilute to 25 ml with mobile phase & shake.

### **Sample Preparation:**

Weigh accurately as required quantities of the sample powdered tablets eq. to 100 mg of Ciprofloxacin in 100 ml volumetric flask add 50 ml of mobile phase and sonicate to completely dissolve, shake and makeup 100 ml with mobile phase & filter. Take 5.0 ml and dilute to 25 ml with mobile phase & shake.

### **Chromatographic system:**

Inject the standard and sample solutions. If the tailing factor more than 2.0 and column efficiency is less than 2000 theoretical plates the test is not valid. The relative standard deviation for replicate injection is not more than 2.0 %. Inject the test solution and reference solution.

#### Sample Dilutions: By .....

- (A) Take ----mg of the sample and proceed as per above.
- **(B)** Take ----mg of the sample and proceed as per above.
- (C) Take ----mg of the sample and proceed as per above.
- (**D**) Take ----mg of the sample and proceed as per above.
- (**E**) Take ----mg of the sample and proceed as per above.
- **(F)** Take -----mg of the sample and proceed as per above.

### Test data collection sheet:

| S.No. | Standards  | Area |
|-------|------------|------|
| 1.    | Standard-1 |      |
| 2.    | Standard-2 |      |
| 3.    | Standard-3 |      |
| 4.    | Standard-4 |      |
| 5.    | Standard-5 |      |
| 6.    | Standard-6 |      |



QUALITY ASSURANCE DEPARTMENT

# ANALYTICAL METHOD VALIDATION/VERIFICATION PROTOCOL FOR CIPROFLOXACIN TABLETS USP 500 MG

| 7. | Mean |  |
|----|------|--|
| 8. | %RSD |  |

Acceptance Criteria: RSD is not more than 2.0%

### Test Data Collection:-

| Samples  |    | Sample Area | Mean |
|----------|----|-------------|------|
| Sample A | T1 |             |      |
|          | T2 |             |      |
| Sample B | T1 |             |      |
|          | T2 |             |      |
| Sample C | T1 |             |      |
|          | T2 |             |      |
| Sample D | T1 |             |      |
|          | T2 |             |      |
| Sample E | T1 |             |      |
|          | T2 |             |      |
| Sample F | T1 |             |      |
|          | T2 |             |      |

#### **Calculation:**

### Table for Six Replicate Assays:

| Sample Number | Estimated % Amount | Mean | % RSD |
|---------------|--------------------|------|-------|
| Sample A      |                    |      |       |
| Sample B      |                    |      |       |
| Sample C      |                    |      |       |
| Sample D      |                    |      |       |
| Sample E      |                    |      |       |
| Sample F      |                    |      |       |

### Intermediate Precision -

(Within laboratory variations such as different days, analyst & equipments):

### Analyst (II) Anurag Singh:-

### **Chromatographic Condition:-**

- a stainless steel column 25 cm x 4.6 mm, packed with octadecylesilane bonded to porous silica (5 um),
- Flow rate 1.5 ml per minute,
- spectrophotometer set at 278 nm,
- Injection volume 10 μl.
- Column temperature of 40°.



QUALITY ASSURANCE DEPARTMENT

# ANALYTICAL METHOD VALIDATION/VERIFICATION PROTOCOL FOR CIPROFLOXACIN TABLETS USP 500 MG

#### **Mobile Phase:**

A mixture of 13 volumes of Acetonitrile and 87 volumes of a 0.245% w/v solution of Orthophosphoric acid the pH of which has been adjusted to 3.0 with triethylamine. Then degas and filter through with 0.45  $\mu m$  filter paper.

### **Standard preparation:**

Weigh accurately-----mg (about 116mg) of Ciprofloxacin Hydrochloride working standard in 100 ml volumetric flask add 50 ml of mobile phase and sonicate to completely dissolve, shake and makeup 100 ml with mobile phase & filter. Take 5.0ml and dilute to 25 ml with mobile phase & shake.

### **Sample Preparation:**

Weigh accurately as required quantities of the sample powdered tablets eq. to 100mg of Ciprofloxacin in 100ml volumetric flask add 50 ml of mobile phase and sonicate to completely dissolve, shake and makeup 100 ml with mobile phase & filter. Take 5.0ml and dilute to 25 ml with mobile phase & shake.

### **Chromatographic system:**

Inject the standard and sample solutions. If the tailing factor more than 2.0 and column efficiency is less than 2000 theoretical plates the test is not valid. The relative standard deviation for replicate injection is not more than 2.0 %. Inject the test solution and reference solution.

### **Sample Dilutions:**

- (A) Take -----mg of the sample and proceed as per above.
- **(B)** Take ----mg of the sample and proceed as per above.
- **(C)** Take ----mg of the sample and proceed as per above.
- (**D**) Take ----mg of the sample and proceed as per above.
- (E) Take ----mg of the sample and proceed as per above.
- (**F**) Take -----mg of the sample and proceed as per above.

#### **Test data collection sheet:**

| S.No. | Standards  | Area |
|-------|------------|------|
| 1.    | Standard-1 |      |
| 2.    | Standard-2 |      |
| 3.    | Standard-3 |      |
| 4.    | Standard-4 |      |
| 5.    | Standard-5 |      |
| 6.    | Standard-6 |      |
| 7.    | Mean       |      |



QUALITY ASSURANCE DEPARTMENT

# ANALYTICAL METHOD VALIDATION/VERIFICATION PROTOCOL FOR CIPROFLOXACIN TABLETS USP 500 MG

| 8. %RSD |  |
|---------|--|
|---------|--|

Acceptance Criteria: RSD is not more than 2.0%

### **Test Data Collection:-**

| Samples  |    | Sample Area | Mean |
|----------|----|-------------|------|
| Sample A | T1 |             |      |
|          | T2 |             |      |
| Sample B | T1 |             |      |
|          | T2 |             |      |
| Sample C | T1 |             |      |
|          | T2 |             |      |
| Sample D | T1 |             |      |
|          | T2 |             |      |
| Sample E | T1 |             |      |
|          | T2 |             |      |
| Sample F | T1 |             |      |
|          | T2 |             |      |

### **Calculation:**

Table for Six Replicate Assays:

| Sample Number | Estimated % Amount | Mean | % RSD |
|---------------|--------------------|------|-------|
| Sample A      |                    |      |       |
| Sample B      |                    |      |       |
| Sample C      |                    |      |       |
| Sample D      |                    |      |       |
| Sample E      |                    |      |       |
| Sample F      |                    |      |       |

### Table for Six Replicate Assays analyst by two different Analysts & days:

Test Data analyst by Bhoopendra Singh-

Table for Six Replicate Assays

| Sample Number | Estimated % Amount | Mean | % RSD |
|---------------|--------------------|------|-------|
| Sample A      |                    |      |       |
| Sample B      |                    |      |       |
| Sample C      |                    |      |       |
| Sample D      |                    |      |       |
| Sample E      |                    |      |       |
| Sample F      |                    |      |       |

Test Data analyst by Anurag Singh-

Table for Six Replicate Assays

|               | ·                         |      |       |  |
|---------------|---------------------------|------|-------|--|
| Sample Number | <b>Estimated % Amount</b> | Mean | % RSD |  |



QUALITY ASSURANCE DEPARTMENT

# ANALYTICAL METHOD VALIDATION/VERIFICATION PROTOCOL FOR CIPROFLOXACIN TABLETS USP 500 MG

| Sample A |  |  |
|----------|--|--|
| Sample B |  |  |
| Sample C |  |  |
| Sample D |  |  |
| Sample E |  |  |
| Sample F |  |  |

**Acceptance Criteria:** NMT 2 % (% of Relative Standard Deviation).

#### **Robustness:**

To demonstrate the analytical method is capable to yield reproducibility results under; small but deliberate variations in method parameters during normal usage such as composition & Flow rate of mobile phase.

### **Procedure:**

Perform the robustness study by injecting single of resolution solution & standard solution for six times for the following parameters.

- Change in ratio of the mobile phase. Record the observation in below observation table.
- Change in Flow rate of mobile phase. Record the observation in below observation table.

#### **Observation Table:-**

### Change ratio in the mobile phase at 278 nm

| Mobile phase |              | Flow rate  | System suitability |             |         |
|--------------|--------------|------------|--------------------|-------------|---------|
| Buffer       | Acetonitrile | ml/min     | Retention          | Theoretical | Tailing |
|              |              |            | Time               | Plates      | Factor  |
| 875 ml       | 125 ml       | 1.5 ml/min |                    |             |         |
| 870 ml       | 130 ml       | 1.5 ml/min |                    |             |         |
| 865 ml       | 135 ml       | 1.5 ml/min |                    |             |         |

### Change in flow rate at 278 nm

| Mobile phase |              | Change in  | System Suitability |                       |                |
|--------------|--------------|------------|--------------------|-----------------------|----------------|
| Buffer       | Acetonitrile | Flow rate  | Retention<br>time  | Theoretical<br>Plates | Tailing Factor |
| 870 ml       | 130 ml       | 1.4 ml/min |                    |                       |                |
| 870 ml       | 130 ml       | 1.5 ml/min |                    |                       |                |
| 870 ml       | 130 ml       | 1.6 ml/min |                    |                       |                |

### Acceptance criteria:



QUALITY ASSURANCE DEPARTMENT

# ANALYTICAL METHOD VALIDATION/VERIFICATION PROTOCOL FOR CIPROFLOXACIN TABLETS USP 500 MG

|    | TABLETS USP 500 N  | MG             |
|----|--|----------------|
|    | lytical method validation shall be robust (i.e. Theoretical Pla ot more than 2.0). |                |
| An | alysed By/On:  | Checked By/On: |
|    |  |                |
|    |  |                |
|    |  |                |
|    |  |                |